衞生署藥物辦公室
藥物資訊及警戒科
香港九龍觀塘巧明街 100 號
Landmark East 友邦九龍大樓
20 樓 2002-05 室

DEPARTMENT OF HEALTH
DRUG OFFICE
DRUG INFORMATION AND PHARMACOVIGILANCE DIVISION
Suites 2002-05, 20/F, AIA Kowloon Tower,
Landmark East, 100 How Ming Street,
Kwun Tong, Kowloon, Hong Kong

電話號碼 Tel. No.: 3974 4175
詢問處 Enquiries: (852) 3974 4175
傳真號碼 Faxline No.: (852) 2803 4962
本署檔號 OUR REF.:
(來函請敍明此檔案號碼) DH DO DIMC/7-30/1
(IN REPLY PLEASE QUOTE THIS FILE REF.)

16 Dec 2022

Dear Healthcare Professionals,

Update to Fact Sheets of Paxlovid (nirmatrelvir 300mg co-packaged with ritonavir 100mg) tablets with new safety information and microbiological data

Your attention is drawn to the Singapore Health Sciences Authority's (HSA) announcement that a Dear Healthcare Professional Letter has been issued by Pfizer Private Limited to inform healthcare professionals of updates to the Paxlovid Fact Sheets for Healthcare Providers and Patients/Caregivers.

The updates to the Fact Sheets include the addition of anaphylaxis as adverse reaction, addition of new drug interactions and antiviral data. Healthcare professionals are advised to assess patient's medication and supplement list before starting Paxlovid treatment, and to inform patients to discontinue Paxlovid immediately if they experience any symptoms of allergic reactions.

Please refer to the following website in HSA for details:
https://www.hsa.gov.sg/announcements/dear-healthcare-professional-letter/update-to-fact-sheets-of-paxlovid-(nirmatrelvir-300mg-co-packaged-with-ritonavir-100mg)-tablets-with-new-safety-information-and-microbiological-data

In Hong Kong, Paxlovid Tablets (HK-67360) is a pharmaceutical product registered by Pfizer Corporation Hong Kong Limited. The product is a prescription-only medicine. So far, the Department of Health (DH) has received 58 cases of adverse drug reaction related to Paxlovid, but these cases were not related to anaphylaxis. The DH will remain vigilant on safety update of the product issued by other overseas drug regulatory authorities for consideration of any action deemed necessary.

Please note that this letter serves as a means for the DH to communicate important new safety information about registered pharmaceutical products with healthcare professionals in Hong Kong and is not intended to serve as guidelines or to replace professional clinical judgement. Healthcare professionals are advised to balance the risk of possible adverse effects against the benefit of treatment.

Please report any adverse events caused by drugs to the Adverse Drug Reaction Unit of the DH (tel. no.: 2319 2920, fax: 2319 6319 or email: adr@dh.gov.hk). For details, please refer to the website at Drug Office under "ADR Reporting": http://www.drugoffice.gov.hk/adr.html. You may wish to visit the Drug Office's website for subscription and browsing of "Drug News" which is a monthly digest of drug safety news and information issued by Drug Office.

Yours faithfully,

(Terence MAN)
for Assistant Director (Drug)